/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

A

Akihiko Shimomura

Juntendo University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

258

Papers

3.7K

Citations

28

h-index

69

i10-index

Akihiko Shimomura is an academic researcher from Juntendo University. The author has contributed to research in topics: Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies. The author has an h-index of 28, co-authored 220 publications.

ORCID: 0000-0002-2557-8170

Research Topics

Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers

Papers by this author

works

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

2017 · The Lancet Oncology · 477 citations

https://doi.org/10.1016/s1470-2045(17)30604-6

Toshihiko Doi Kohei Shitara Yoichi Naito Akihiko Shimomura

TERT promoter hotspot mutations in breast cancer

2017 · Breast Cancer · 37 citations

https://doi.org/10.1007/s12282-017-0825-5

Tatsunori Shimoi Masayuki Yoshida Yuka Kitamura Tomomi Yoshino

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

2019 · Investigational New Drugs · 32 citations

https://doi.org/10.1007/s10637-019-00787-3

Takahiro Ebata Toshio Shimizu Yutaka Fujiwara Kenji Tamura

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer

2020 · Breast Cancer Research and Treatment · 31 citations

https://doi.org/10.1007/s10549-020-05580-y

Madoka Iwase Masashi Ando Kenjiro Aogi Tomoyuki Aruga

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status

2014 · The Breast · 28 citations

https://doi.org/10.1016/j.breast.2014.03.008

Maki Tanioka Masaoki Sasaki Akihiko Shimomura Makoto Fujishima

64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer

2017 · Annals of Oncology · 28 citations

https://doi.org/10.1093/annonc/mdx227

Shinsuke Sasada Hayato Kurihara Takayuki Kinoshita Masayuki Yoshida

Research topics

topics

Cancer Treatment and Pharmacology

HER2/EGFR in Cancer Research

Advanced Breast Cancer Therapies

Breast Cancer Treatment Studies

Cancer Immunotherapy and Biomarkers

Chat about Author

Papers

Chat

Click to start Chat